Breakthrough Targeted Cancer Therapeutics with Higher Efficacy and Safety

The company currently has two important and innovative R&D preclinical programs:

The first program is focused on the development of stable, potent and safer drug conjugates carrying cytotoxic agents. Our new lead drug conjugate targeting a specific receptor highly expressed in solid tumors showed a dramatic tumor growth inhibition of multiple triple-negative breast cancer models. A single intravenous injection of 1.4 mg/kg animal weight of the new lead drug conjugate caused a 100% tumor growth inhibition of HCC1806 TNBC model with the majority of mice showing complete response. Toxicology studies showed no effect on animal weight, white blood cells or normal organs suggesting the safety of our new drug conjugate. We have also found that a suboptimal dose of our initial drug conjugate enhances the anti-tumor activity of anti-PD_1 Keytruda using humanized mice bearing BR1126 TNBC patient-derived tumor model. We are looking forward to perform additional oncology and immuno-oncology studies of our lead drug conjugate alone or in combination with Keytruda on preclinical models of metastatic TNBC, ovarian and endometrial patient-derived tumors as well as PK/biodistribution/toxicology studies in cynomolgus monkey. Our goal is to file an IND application to the FDA and initiate Phase 1/2a clinical trial of the lead drug conjugate as monotherapy or combination therapy with Keytruda on patients with metastatic TNBC, ovarian and endometrial cancers.

The second program is dedicated to the development of conjugates delivering immunostimulant drugs to CD_8 T cells and natural killer cells in order to enhance their anti-tumor activity against solid tumors. This program is currently on hold until availability of additional funds.